Careers Who We Are At Exagen, we are constantly pushing for new discoveries in the clinical laboratory. Our focus and dedication to the rheumatology space allows for a deep expertise in the development of advanced testing to aid healthcare providers and their patients throughout the continuum of care. Based in Vista, California, we work hard knowing that our advances are making a difference in people’s lives. We offer competitive employee benefits including: Medical Dental Vision Flexible Benefits for Dependent and Health Care 401 (k) Program Paid Time Off (PTO) Paid Company Holidays Employer Paid Life Insurance Optional Life Insurance Employer-Paid Short-Term Disability Employer-Paid Long-Term Disability If you are ready to join a company that offers more than a job but an opportunity to participate in world class scientific discovery and leading diagnostic advances into the offices of physicians nationwide, then Exagen may be the right place for you. Current Openings ©2021 Exagen Inc. | All Rights Reserved SA1168

AVISE HCQ The Hydroxychloroquine (HCQ) Test Measuring Drug Levels in Whole Blood AVISE® HCQ is an advanced drug monitoring test that provides accurate measurement of hydroxychloroquine (HCQ) levels in whole blood to help physicians assess their patients' exposure to hydroxychloroquine therapy. The AVISE HCQ test is available as a venous test and via a AVISE® Touch low volume capillary device test. Clinical Utility: AVISE HCQ Test Report The AVISE HCQ test is intended for use in patients on hydroxychloroquine (PLAQUENIL) therapy, after steady state (approx. 90-120 days), to help assess the following: Patient compliance to therapy Patient risk for disease flares Therapeutic decision making Download PDF References: Costedoat-Chalumeau N, et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum. 2006 Oct;54(10):3284-90. Costedoat-Chalumeau N, et al. Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Ann Rheum Dis. 2007 Jun;66(6):821-4. Costedoat-Chalumeau N, et al. (2013a) Hydroxychloroquine in Systemic Lupus Erythematosus: Results of a French Multicentre Controlled Trial (PLUS Study). Ann Rheum Dis 72:1786-1792. Costedoat-Chalumeau N, et al. (2013b) Adherence to Treatment in Systemic Lupus Erythematosus Patients. Best Pract Res Clin Rheumatol 27:329-340. Frances C, et al. Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study. Arch Dermatol. 2012 Apr;148(4):479-84. Exagen, Inc. Date on File. View Complete References To learn more about AVISE testing please click the link below. Learn More ©2021 Exagen Inc. | All Rights Reserved SA1168